Bibliographic citations
Acevedo, M., Lujan, A. (2020). Reacciones Adversas Medicamentosas a los antibióticos presentado en pacientes de la Clínica Angloamericana. Lima - 2020 [Tesis, Universidad Privada de Huancayo Franklin Roosevelt]. http://repositorio.uroosevelt.edu.pe/handle/20.500.14140/245
Acevedo, M., Lujan, A. Reacciones Adversas Medicamentosas a los antibióticos presentado en pacientes de la Clínica Angloamericana. Lima - 2020 [Tesis]. : Universidad Privada de Huancayo Franklin Roosevelt; 2020. http://repositorio.uroosevelt.edu.pe/handle/20.500.14140/245
@misc{renati/690908,
title = "Reacciones Adversas Medicamentosas a los antibióticos presentado en pacientes de la Clínica Angloamericana. Lima - 2020",
author = "Lujan Sancho, Ana Felicita",
publisher = "Universidad Privada de Huancayo Franklin Roosevelt",
year = "2020"
}
In the present work, the objective was to determine the percentage of adverse reactions to antibiotics presented in patients of the Anglo-American Clinic. Lima - 2020; to identify and report the ADRs. For this purpose, a descriptive study was designed; taking as a sample 200 clinical histories of patients that went to the Anglo-American Clinic during the period January - August 2020. The results: it was found that 94% of patients did not perform RAMs, the patients who reacted with antibiotics were 6%, instead they presented RAMs to glycopeptides with 2%, followed by carbapenems with 1.5%, by quinolones and macrolides with 1% and finally cephalosporins had an incidence of RAMs with 0. 5%, the severity of RAMs according to the results obtained that had no adverse reaction to the drug was 94%, the patients who had a rapid recovery was 5.0%, and 1% extended the period of hospitalization. CONCLUSIONS: As for complications with antibiotics, 94.0% of patients treated with antibiotics did not have RAMs, and the incidence of glycopeptide was 2%, followed by carbapenems with 1.5%. Reactions by quinolones and macrolides were also obtained with 1% of RAMs and 0.5%, followed by cephalosporins.
This item is licensed under a Creative Commons License